Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-15

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)

View source ↗

Summary

FDA approved a supplemental application for a buprenorphine and naloxone product by Lannett Company, Inc., resulting in approval of this generic combination for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)